United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 17

Name: Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 17 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness

Readiness leader60 Degrees Pharmaceuticals · 45

Strongest available pathEvolus · +19.3%

Widest latest marginAmphastar Pharmaceuticals · 13.6%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1SXTP · Nasdaq

60 Degrees Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Washington, DC, District of Columbia$3.8M market cap

View full Companies Radar profile

45Cautious

Snapshot price$1.08as of page date

Monthly-close return-99.8%since July 2023

FY2025 revenue$0.00B60 DEGREES PHARMACEUTICALS, INC.

Net margin-732.5%FY2025

P/E snapshot-0.3xone ratio, not a verdict

Prism attention1.9%share across these five

Filing track recordRevenue, USD billions

+296.5%

FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 99.1%

52-week position1% through range

$1.01$8.62

News mentions125

Community mentions0partial coverage

U.S.-scope patents56

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position0/100
Capital-event signal63/100
Innovation pulse12/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 10 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2AMPH · Nasdaq

Amphastar Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1996Rancho Cucamonga, California$958.4M market cap

View full Companies Radar profile

44Cautious

Snapshot price$22.53as of page date

Monthly-close return+18.5%five-year window

FY2025 revenue$0.72BAmphastar Pharmaceuticals, Inc.

Net margin13.6%FY2025

P/E snapshot13.3xone ratio, not a verdict

Prism attention8.4%share across these five

Filing track recordRevenue, USD billions

+64.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 13.2%

52-week position40% through range

$16.65$31.26

News mentions550

Community mentions0partial coverage

U.S.-scope patents128

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal64/100
Management stability90/100
Market position8/100
Capital-event signal20/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 2 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3EOLS · Nasdaq

Evolus

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2012Irvine, California$600.4M market cap

View full Companies Radar profile

44Cautious

Snapshot price$9.09as of page date

Monthly-close return+19.3%five-year window

FY2025 revenue$0.30BEvolus, Inc.

Net margin-17.4%FY2025

P/E snapshot32.9xone ratio, not a verdict

Prism attention11.6%share across these five

Filing track recordRevenue, USD billions

+198.2%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 31.4%

52-week position99% through range

$3.86$9.15

News mentions757

Community mentions0partial coverage

U.S.-scope patents31

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal55/100
Management stability90/100
Market position0/100
Capital-event signal71/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 2 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4PRGO · NYSE

Perrigo

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1887LANSING$2.03B market cap

View full Companies Radar profile

44Cautious

Snapshot price$14.64as of page date

Monthly-close return-69.1%five-year window

FY2025 revenue$4.25BPERRIGO Co plc

Net margin-33.5%FY2025

P/E snapshot6.1xone ratio, not a verdict

Prism attention75.7%share across these five

Filing track recordRevenue, USD billions

+2.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.7%

52-week position37% through range

$9.23$23.95

News mentions5.0K

Community mentions632partial coverage

U.S.-scope patents95

Prism InsightsWhat sits behind the readiness signal
Observed risk 18/100higher means more observed risk

Earnings signal41/100
Management stability90/100
Market position35/100
Capital-event signal76/100
Innovation pulse18/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 137 M&A involvements, 42 asset-acquisition events and 14 contract events.

Innovation activity

Prism records 6 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 9 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5VREOF · OTCQX

Vireo Growth

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2014Minneapolis, Minnesota$542.7M market cap

View full Companies Radar profile

44Cautious

Snapshot price$10.52as of page date

Monthly-close return-78.1%five-year window

FY2025 revenue$0.27BVireo Growth Inc.

Net margin-25.3%FY2025

P/E snapshot5.4xone ratio, not a verdict

Prism attention2.4%share across these five

Filing track recordRevenue, USD billions

+393.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 49.1%

52-week position12% through range

$8.91$22.50

News mentions160

Community mentions0partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 2/100higher means more observed risk

Earnings signal75/100
Management stability70/100
Market position26/100
Capital-event signal25/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 30 M&A involvements, 9 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Evolus

+19.3%

Amphastar Pharmaceuticals

+18.5%

Perrigo

-69.1%

Vireo Growth

-78.1%

60 Degrees Pharmaceuticals

-99.8%

Latest revenue

USD billions, official filing scope shown on each company card.

Perrigo

$4.25B

Amphastar Pharmaceuticals

$0.72B

Evolus

$0.30B

Vireo Growth

$0.27B

60 Degrees Pharmaceuticals

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Amphastar Pharmaceuticals

13.6%

Evolus

-17.4%

Vireo Growth

-25.3%

Perrigo

-33.5%

60 Degrees Pharmaceuticals

-732.5%

Prism news attention

Normalized share across these five names; attention is not quality.

Perrigo

75.7%

Evolus

11.6%

Amphastar Pharmaceuticals

8.4%

Vireo Growth

2.4%

60 Degrees Pharmaceuticals

1.9%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Perrigo leads the conversation

It holds 75.7% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $4.25B.

Price path

Evolus leads the available price paths

Its monthly-close return is +19.3% for the five-year window. At the other end, 60 Degrees Pharmaceuticals is -99.8% for its since July 2023. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Amphastar Pharmaceuticals has the widest latest margin

Its FY2025 net margin is 13.6%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

60 Degrees Pharmaceuticals shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -0.3x while its since July 2023 price return is -99.8%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · PRGO

Perrigo

4,952available Prism news records

Prism top themes

Price action & investor response

103

Earnings & financial performance

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+11.3%316 latest 12m vs 284 prior 12m

Machine-classified coverage tone

66.9% positive-3.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 11wearable tech 10wearable device 10private equity 10earnings report 9ceo change 8earnings surprises 8generic drug approval 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-06-15 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

PRGO

Perrigo

632 mentions

Products, pricing and logistics

427

Stock and valuation

Workplace and hiring

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 632 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

SXTP

60 Degrees Pharmaceuticals

through 2026-04-03

Earnings releases 12Company announcements 9Listing / IPO 3Business contracts 1Leadership changes 1

2026-04-03
Earnings releases
HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.58) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.21) EPS, FY2027 earnings at ($0.54) EPS and FY2028 earnings at ($0.44) EPS.
2026-01-16
Company announcements
60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq").
2024-07-25
Business contracts
60 Degrees Pharmaceuticals has been awarded a contract with the United States Army Medical Materiel Development Activity to facilitate commercial validation of new bottle and replacement blister packaging of ARAKODA™ (tafenoquine), the Company's FDA-approved product indicated for malaria prevention.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AMPH

Amphastar Pharmaceuticals

through 2025-05-07

Earnings releases 20Asset acquisitions 2M&A 1

2025-05-07
Earnings releases
Amphastar Pharmaceuticals (AMPH) reported $170.53 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 0.8%. EPS of $0.74 for the same period compares to $1.04 a year ago.
2025-02-14
Asset acquisitions
Eli Lilly and Co. is selling worldwide rights to its hypoglycemia nasal treatment Baqsimi to Amphastar Pharmaceuticals Inc. in a deal potentially worth over $1 billion.
2023-06-30
M&A
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today announced that it has completed the previously announced acquisition of BAQSIMI® from Eli Lilly and Company ("Lilly") (the "Acquisition").

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EOLS

Evolus

through 2026-05-04

Earnings releases 28Regulatory 5Company announcements 4Leadership changes 4Business contracts 1

2026-05-04
Earnings releases
Evolus Inc. today released first quarter results that exceeded analysts’ expectations.
2025-09-09
Leadership changes
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025.
2025-02-14
Listing / IPO
Evolus Inc. priced its IPO of 5 million shares at $12 per share, the low end of its previously proposed range, for gross proceeds of $60 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PRGO

Perrigo

through 2026-04-30

Earnings releases 22Leadership changes 13Lawsuits 5M&A 5Company announcements 4

2026-04-30
Asset acquisitions
Perrigo Company plc ... today announced that it has completed the previously announced sale of its branded Dermacosmetics business to Karo Healthcare for total consideration of up to €332.6 million.
2026-02-26
Earnings releases
Net sales of $1.11 billion decreased 2.5%, or $29 million, including favorable currency translation of 2.3% and divestitures and exited products of -0.4%.
2026-02-17
Lawsuits
An investor who purchased shares of Perrigo Company plc (NYSE: PRGO), filed a lawsuit over alleged violations of Federal Securities Laws by Perrigo Company plc.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VREOF

Vireo Growth

through 2026-04-30

M&A 24Asset acquisitions 9Earnings releases 6Business contracts 2Lawsuits 1

2026-04-30
M&A
Multistate operator Vireo Growth Inc. signed a definitive agreement to acquire multistate operator FLUENT Corp. in an all-stock transaction.
2026-03-31
Asset acquisitions
Vireo Growth is planning to buy The Hawthorne Gardening Company, which sells products like plant nutrients, grow lights, and gardening supplies for indoor and hydroponic (soil-free) gardening across North America.
2026-03-17
Earnings releases
Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 81–88. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

60 Degrees Pharmaceuticals leads the readiness ranking

Its Prism readiness score is 45/100, the highest in this five-company comparison.

Open 60 Degrees Pharmaceuticals in Companies Radar

Scale and margin leadership sit with Perrigo and Amphastar Pharmaceuticals

Perrigo has the largest displayed latest revenue at $4.25B; Amphastar Pharmaceuticals has the widest displayed latest margin at 13.6%.

Open Perrigo in Companies Radar Open Amphastar Pharmaceuticals in Companies Radar

Comparisons

Strongest versus weakest available price path

Evolus is +19.3% for its five-year window; 60 Degrees Pharmaceuticals is -99.8% for its since July 2023.

Open Evolus in Companies Radar Open 60 Degrees Pharmaceuticals in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $4.25B for Perrigo to $0.00B for 60 Degrees Pharmaceuticals. Entity and filing-period labels remain visible on the company cards.

Open Perrigo in Companies Radar Open 60 Degrees Pharmaceuticals in Companies Radar

Anomalies

60 Degrees Pharmaceuticals has the widest attention-readiness rank gap

It ranks #5 by measured news attention (1.9%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open 60 Degrees Pharmaceuticals in Companies Radar

Vireo Growth shows a price-operating divergence to inspect

Its displayed filing-revenue change is +393.6% while its available monthly-close return is -78.1%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Vireo Growth in Companies Radar

Explanations

Attention measures coverage volume, not quality

Perrigo's 75.7% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Perrigo in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open 60 Degrees Pharmaceuticals's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 45/100 score.

Open 60 Degrees Pharmaceuticals in Companies Radar

Stress-test the largest divergence before forming a view

Compare Vireo Growth's profile with Evolus's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Vireo Growth in Companies Radar Open Evolus in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.